These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34360740)

  • 1. Transcriptomic and Metabolic Network Analysis of Metabolic Reprogramming and IGF-1 Modulation in SCA3 Transgenic Mice.
    Lin YT; Lin YS; Cheng WL; Chang JC; Chao YC; Liu CS; Wei AC
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone rescue cerebellar degeneration in SCA3 transgenic mice.
    Wu S; Liu K; Cheng W; Su S; Lin Y; Lin T; Cheng Y; Chang J; Wu Y; Liu C
    Biochem Biophys Res Commun; 2020 Aug; 529(2):467-473. PubMed ID: 32703453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
    Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
    Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
    Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
    Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3/MJD Mouse.
    Wiatr K; Piasecki P; Marczak Ł; Wojciechowski P; Kurkowiak M; Płoski R; Rydzanicz M; Handschuh L; Jungverdorben J; Brüstle O; Figlerowicz M; Figiel M
    Mol Neurobiol; 2019 Dec; 56(12):8168-8202. PubMed ID: 31201651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
    Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
    J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
    Da Silva JD; Teixeira-Castro A; Maciel P
    Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.
    Nóbrega C; Mendonça L; Marcelo A; Lamazière A; Tomé S; Despres G; Matos CA; Mechmet F; Langui D; den Dunnen W; de Almeida LP; Cartier N; Alves S
    Acta Neuropathol; 2019 Nov; 138(5):837-858. PubMed ID: 31197505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
    Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
    Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
    Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
    Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
    Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL
    Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
    Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
    Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
    Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
    Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A.
    Hayer SN; Schelling Y; Huebener-Schmid J; Weber JJ; Hauser S; Schöls L
    Stem Cell Res; 2018 Jul; 30():171-174. PubMed ID: 29936336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of MicroRNAs in Spinocerebellar Ataxia Type 3.
    Krauss S; Evert BO
    J Mol Biol; 2019 Apr; 431(9):1729-1742. PubMed ID: 30664869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3.
    Lin YS; Cheng WL; Chang JC; Lin TT; Chao YC; Liu CS
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.